HK Stock Market Move | BIOCYTOGEN-B (02315) surged over 10% and signed an antibody selection evaluation agreement with Merck to advance antibody conjugated lipid delivery solutions.

BioCytoGen-B(02315) rose more than 10%, as of the time of writing, it rose by 10.43% to HK$25.4, with a turnover of HK$1088.22 million. On the news front, recently, according to official news from Baiosaitu, the company has signed an evaluation agreement for antibody selection rights with the global leading technology company, Merck. This agreement aims to advance the development of antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP). Under the terms of the agreement, Baiosaitu will provide fully human antibodies developed based on its RenMice platform for Merck to evaluate their feasibility for use in antibody-conjugated LNP formulation services. Merck has been granted the exclusive option to acquire the rights to selected antibody assets, while Baiosaitu is entitled to receive corresponding fees, sales royalties, and sublicensing royalties. It is reported that Baiosaitu is currently scaling up drug development for over 1,000 potential drug targets through its "Thousands of Mice and Antibodies" program, and has established a database of over 1 million fully human antibody sequences for global collaboration. As of June 30, 2025, Baiosaitu has signed approximately 280 drug development/co-development/licensing/transfer agreements, and has reached agreements on more than 50 target projects with companies, including multiple MNCs, through the RenMice platform for antibody development. Several clinical-stage antibody molecules have also reached external licensing partnerships.